Alvotech

ALVOW·NasdaqGM
Compare
0.44960.0000 (0.00%)today
At close: Oct 6, 10:44 AM EDT · May be delayed up to 15 min · USD

Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.

Key statistics

Previous close0.4496
Open1.5200
Day range0.44960.4500
52-week range0.44960.4500
Off day high−0.09%
Off 52-week high−0.09%
Volume5.00
Avg. volume (3M)—
Market cap—
EPS (TTM)—
Forward P/E—
P/E ratio (TTM)—
Dividend yield—
Beta (5Y)0.21
Shares outstanding—
Short interest—
Earnings date—
Analyst target—
Profit margin−36.31%

Against its peers

Compare in full ›
ALVOW BIIB ALDX ALNY ROIV REGN
Market cap — 34.37B 42.23M 31.02B 24.22B 81.41B
P/E (TTM) — 41.3 — 39.1 — 19.6
Forward P/E — 14.1 -2.5 18.6 -19.5 12.8
Price/book -0.8 1.8 1.1 22.9 5.7 2.5
Dividend yield — — — — — 0.48%
1-year change — +58.66% −87.13% −52.81% +89.01% +37.10%
Today 0.00% −1.15% −5.05% −0.94% −1.50% −0.70%

The closest companies by business. Prices may be delayed up to 15 min.

Latest news

All ALVOW news ›
@clin_trials·

Alvotech, Advanz Submit First Eylea 8 mg Biosimilar Bid

BioPharm International Alvotech and Advanz Pharma announced October 14, 2026, the submission of a European regulatory application for AVT29, a proposed biosimilar to Eylea 8 mg (aflibercept 114.3 mg/mL), which is marketed as Eylea HD in…

@OphthTimes·Positive

Alvotech files first known aflibercept 8 mg biosimilar with EMA

Ophthalmology Times Alvotech files first known aflibercept 8 mg biosimilar with EMA AVT29, filed as a line extension to Mynzepli, reaches EMA before its phase 3 comparative trial in DME reads out in mid-2027. Alvotech and Advanz Pharma…

From articles in the 4Search news index.

In the news

42mentions in 30 days
42with it in the headline
Positivesentiment

Finance and business coverage in the 4Conservative news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 42 articles, not a forecast.

Market data is provided for information only and comes from free public sources. Prices may be delayed up to 15 minutes; data may be incomplete or inaccurate. Nothing on this page is investment advice or a recommendation to buy or sell any security. News and coverage analytics are drawn from the 4Conservative index. Terms of use.